BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vafseo (Vadadustat) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Vafseo (Vadadustat)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07565701-874@assetmemo.bio
DTSTAMP:20261121T005607Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Vafseo (Vadadustat): Phase 3 readout est. (NCT07565701)
DESCRIPTION:Vafseo (Vadadustat)\, phase 3\, Chronic Kidney Disease.\nStudy:
  Safety and Efficacy of a Phased Transition From Epogen to Three Times Wee
 kly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-C
 enter Hemodialysis\nEstimated primary completion: April 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/vadadustat#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07565701
URL:https://assetmemo.bio/drug/vadadustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07086755-874@assetmemo.bio
DTSTAMP:20261121T005607Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Vafseo (Vadadustat): Phase 2/3 readout est. (NCT07086755)
DESCRIPTION:Vafseo (Vadadustat)\, phase 2/3.\nStudy: Vadadustat for the Tre
 atment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen
 -Associated Lung Injury\nEstimated primary completion: 31 May 2031. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/vadadustat#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07086755
URL:https://assetmemo.bio/drug/vadadustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
